{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:54:15Z","timestamp":1745855655215},"reference-count":21,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,17]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>Leishmaniasis is a protozoan disease caused by species of genus <jats:italic>Leishmania.<\/jats:italic> Immunosuppression increases the risk of severe clinical forms and impairs response to treatment. The expansion of the use of immunomodulatory drugs for different conditions has raised the number of these cases. In this report, we present a case of visceral leishmaniasis in a patient with multiple sclerosis (MS) under fingolimod treatment. He presented with the triad of fever, visceromegaly, and pancytopenia and was diagnosed by the presence of amastigotes in a bone marrow sample. Furthermore, we discuss the previous published cases of MS patients under different immunosuppressant therapies to highlight its risk in endemic areas and suggest a therapeutic approach.<\/jats:p>","DOI":"10.4269\/ajtmh.22-0117","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:13:23Z","timestamp":1657026803000},"page":"339-341","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis"],"prefix":"10.4269","volume":"107","author":[{"given":"Alvaro","family":"Guerra-Amor","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Universitari Vall d\u2019Hebr\u00f3n, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitari Vall d\u2019Hebr\u00f3n, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Bosch-Nicolau","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breogan","family":"Rodriguez-Acevedo","sequence":"additional","affiliation":[{"name":"Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Zabalza","sequence":"additional","affiliation":[{"name":"Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sulleiro","sequence":"additional","affiliation":[{"name":"Microbiology Department, University Hospital Vall d\u2019Hebr\u00f3n, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Espinosa-Pereiro","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Aznar","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez-Montalv\u00e1","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Molina","sequence":"additional","affiliation":[{"name":"Tropical Medicine & International Health Unit Vall d\u2019Hebr\u00f3n\u2014Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018"},{"key":"b2","series-title":"Infez Med","first-page":"265","article-title":"Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines","volume":"24","author":"Pagliano","year":"2016"},{"key":"b3","series-title":"Acta Trop","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.actatropica.2003.09.009","article-title":"Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis","volume":"90","author":"Fern\u00e1ndez-Guerrero","year":"2004"},{"key":"b4","series-title":"BMC Infect Dis","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1471-2334-6-177","article-title":"Leishmania infantum leishmaniasis in corticosteroid\u2013treated patients","volume":"6","author":"Pittalis","year":"2006"},{"key":"b5","series-title":"J Crohn\u2019s Colitis","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/ecco-jcc\/jjx067","article-title":"Visceral leishmaniasis infection in a patient with Crohn\u2019s disease treated with azathioprine","volume":"11","author":"Vald\u00e9s Delgado","year":"2017"},{"key":"b6","series-title":"PLoS Negl Trop Dis","doi-asserted-by":"publisher","first-page":"e0007708","DOI":"10.1371\/journal.pntd.0007708","article-title":"Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression","volume":"13","author":"Bosch-Nicolau","year":"2019"},{"key":"b7","series-title":"Transplantation","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/TP.0000000000002018","article-title":"Visceral and cutaneous leishmaniasis recommendations for solid organ transplant recipients and donors","volume":"102","author":"Clemente","year":"2018"},{"key":"b8","series-title":"Nat Rev Neurol","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis\u2014success from bench to bedside","volume":"15","author":"Tintore","year":"2019"},{"key":"b9","series-title":"J Neurol Sci","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013"},{"key":"b10","series-title":"Nat Rev Neurol","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016"},{"key":"b11","series-title":"Mult Scler","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1352458514555788","article-title":"Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient","volume":"21","author":"Artemiadis","year":"2015"},{"key":"b12","series-title":"Neurologia","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.nrl.2017.01.021","article-title":"Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Leishmaniasis cut\u00e1nea agresiva en paciente con esclerosis m\u00faltiple tratada con fingolimod","volume":"33","author":"Hern\u00e1ndez Clares","year":"2018"},{"key":"b13","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.4269\/ajtmh.19-0841","article-title":"Case report: confirmation by metagenomic sequencing of visceral leishmaniasis in an immunosuppressed returned traveler","volume":"103","author":"Williams","year":"2020"},{"key":"b14","series-title":"Int J Dermatol","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1046\/j.1365-4362.2003.01730.x","article-title":"Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid","volume":"42","author":"Motta","year":"2003"},{"key":"b15","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.4269\/ajtmh.19-0259","article-title":"Case report: mucocutaneous leishmaniasis masquerading as idiopathic midline granulomatous disease","volume":"101","author":"Tejura","year":"2019"},{"key":"b16","year":"2015"},{"key":"b17","series-title":"Br J Haematol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2141.2011.08802.x","article-title":"Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia","volume":"156","author":"Pitini","year":"2012"},{"key":"b18","series-title":"Infection","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s15010-011-0109-5","article-title":"Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment","volume":"39","author":"Casabianca","year":"2011"},{"key":"b19","series-title":"Med Clin (Barc)","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.medcli.2019.07.026","article-title":"Risk of infection associated with new therapies for lymphoproliferative syndromes. Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos","volume":"154","author":"Los-Arcos","year":"2020"},{"key":"b20","series-title":"J Immunol","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.4049\/jimmunol.172.12.7574","article-title":"Protection against progressive leishmaniasis by IFN-beta","volume":"172","author":"Mattner","year":"2004"},{"key":"b21","series-title":"Cell Rep","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.celrep.2020.01.099","article-title":"Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis","volume":"30","author":"Kumar","year":"2020"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/2\/article-p339.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/2\/article-p339.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/2\/article-p339.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:14:35Z","timestamp":1660742075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/2\/article-p339.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":21,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.22-0117","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}